Pulmonary hypertension (PH) is a complex and often misunderstood condition. This article aims to provide a comprehensive overview of PH, its pathophysiology, clinical presentation, diagnosis, and management.
PH is characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, leading to right heart failure. The pathophysiology involves vasoconstriction, vascular remodeling, and thrombosis in situ. It is classified into five groups based on the underlying cause, each having distinct pathophysiological mechanisms.
PH often presents nonspecifically, making it challenging to diagnose. Common symptoms include dyspnea, fatigue, chest pain, and syncope. Physical examination may reveal signs of right heart failure, including jugular venous distention, hepatomegaly, and peripheral edema.
Diagnosis involves a high index of suspicion, given the nonspecific presentation. Initial evaluation includes echocardiography, followed by right heart catheterization - the gold standard for diagnosis. Additional tests help classify PH and identify the underlying cause.
Management strategies are tailored according to the PH classification. General measures include supplemental oxygen, diuretics, and anticoagulation. Specific therapies target pathophysiological mechanisms, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. In severe cases, lung transplantation may be considered.
PH is a complex condition requiring a comprehensive understanding for effective management. Early recognition, accurate classification, and appropriate management can significantly improve patient outcomes. As healthcare professionals, continuous learning and staying updated on recent advancements are crucial in managing this challenging condition.
1.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
2.
From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study
3.
Year in Review: Non-Small Cell Lung Cancer
4.
FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.
5.
Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
1.
Targeted Therapies for Breast Cancer: What’s New?
2.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
3.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
4.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
5.
Sorafenib: Understanding the science behind a powerful cancer drug
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Common Cancer Myths Debunked
5.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation